EUROTARGET

European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity

 Coordinatore STICHTING KATHOLIEKE UNIVERSITEIT 

 Organization address address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ

contact info
Titolo: Mr.
Nome: Wim
Cognome: Van Oijen
Email: send email
Telefono: +31 24 3618937
Fax: +31 24 3540529

 Nazionalità Coordinatore Netherlands [NL]
 Sito del progetto http://www.eurotargetproject.eu
 Totale costo 7˙818˙366 €
 EC contributo 5˙999˙550 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-03-01   -   2016-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT

 Organization address address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ

contact info
Titolo: Mr.
Nome: Wim
Cognome: Van Oijen
Email: send email
Telefono: +31 24 3618937
Fax: +31 24 3540529

NL (NIJMEGEN) coordinator 1˙792˙400.00
2    ISLENSK ERFDAGREINING EHF

 Organization address address: Sturlugata 8
city: REYKJAVIK
postcode: 101

contact info
Titolo: Mr.
Nome: Bjorgvin
Cognome: Richardsson
Email: send email
Telefono: +354 570 1821
Fax: +354 570 1903

IS (REYKJAVIK) participant 787˙550.00
3    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

 Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908

contact info
Titolo: Ms.
Nome: Anaïs
Cognome: González
Email: send email
Telefono: 34932607245
Fax: 34932607219

ES (L'HOSPITALET DE LLOBREGAT) participant 550˙000.00
4    CESAR CENTRAL EUROPEAN SOCIETY FOR ANTICANCER DRUG RESEARCH EWIV

 Organization address address: HANGLUSSGASSE 4 1 3
city: WIEN
postcode: 1150

contact info
Titolo: Dr.
Nome: Berta
Cognome: Moritz
Email: send email
Telefono: +43 1 522 309312
Fax: +43 1 522 309314

AT (WIEN) participant 521˙475.00
5    Pamgene International BV

 Organization address address: Nieuwstraat 30
city: 'S-HERTOGENBOSCH
postcode: 5211NL

contact info
Titolo: Ms.
Nome: Martine
Cognome: Hulselmans
Email: send email
Telefono: +31 73 6158083
Fax: +31 73 615 8081

NL ('S-HERTOGENBOSCH) participant 471˙500.00
6    UNIVERSITAET DES SAARLANDES

 Organization address address: CAMPUS
city: SAARBRUECKEN
postcode: 66041

contact info
Titolo: Dr.
Nome: Vera
Cognome: Schneider
Email: send email
Telefono: +49 681 95923385
Fax: +49 681 95923370

DE (SAARBRUECKEN) participant 428˙128.50
7    STICHTING HET NEDERLANDS KANKER INSTITUUT

 Organization address address: PLESMANLAAN 121
city: AMSTERDAM
postcode: 1066 CX

contact info
Titolo: Dr.
Nome: Henri
Cognome: Van Luenen
Email: send email
Telefono: +31 20 512 2097
Fax: +31 20 6691383

NL (AMSTERDAM) participant 373˙200.00
8    Cambridge University Hospitals NHS Foundation Trust

 Organization address address: Hills Rd
city: Cambridge
postcode: CB2 0QQ

contact info
Titolo: Mr.
Nome: Stephen
Cognome: Kelleher
Email: send email
Telefono: +44 1223 217418

UK (Cambridge) participant 327˙648.00
9    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Ms.
Nome: Marlina
Cognome: Vos
Email: send email
Telefono: +31 71 526 1302
Fax: +31 71 526 6980

NL (LEIDEN) participant 258˙000.00
10    RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN

 Organization address address: REGINA PACIS WEG 3
city: BONN
postcode: 53113

contact info
Titolo: Ms.
Nome: Daniela
Cognome: Hasenpusch
Email: send email
Telefono: +49 228 73 7274
Fax: +49 228 73 6479

DE (BONN) participant 163˙200.00
11    GRUPO ESPANOL DE TRATAMIENTO DE TUMORES UROLOGICOS ASOCIACION

 Organization address address: CALLE VELAZQUEZ 7
city: MADRID
postcode: 28001

contact info
Titolo: Mrs.
Nome: Yasmina
Cognome: Bernabe
Email: send email
Telefono: 34934511724

ES (MADRID) participant 97˙125.00
12    Nome Ente NON disponibile

 Organization address city: Jena
postcode: 7740

contact info
Titolo: Dr.
Nome: Kerstin
Cognome: Junker
Email: send email
Telefono: +49 3641 935199
Fax: +49 3641 935768

DE (Jena) participant 82˙171.50
13    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Ms.
Nome: Muriel
Cognome: Bouas
Email: send email
Telefono: +33 5 62748395
Fax: +33 5 61319752

FR (PARIS) participant 80˙000.00
14    UNIVERSITATEA DE MEDICINA SI FARMACIE'CAROL DAVILA' DIN BUCURESTI

 Organization address address: Dionisie Lupu 37
city: BUCHAREST
postcode: 20021

contact info
Titolo: Ms.
Nome: Ioana
Cognome: Ciocan
Email: send email
Telefono: 40213180718
Fax: 40213180729

RO (BUCHAREST) participant 48˙000.00
15    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Mr.
Nome: Keith
Cognome: Cann
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 19˙152.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

extremely    groups    individual    tumor    markers    poor    renal    patients    therapy    predict    becoming    agents    stratification    criteria    patient    validated    treatment    resistance    mrcc       arrays    risk    cancer    compounds    expression    toxicity   

 Obiettivo del progetto (Objective)

'Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical practice for patients with mRCC dramatically. Both response and toxicity to these expensive drugs is, however, extremely variable. With an increasing number of compounds becoming available, choice of compounds and sequence is becoming extraordinary challenging. Classical patient and tumor characteristics appear to have poor predictive ability. The aim of this project is to identify germline genetic markers that predict response and toxicity (by the use of high-resolution whole genome SNP arrays in groups of hundreds of patients treated with different agents), identify expression and epigenetic markers in tumors that predict response (by comparing expression and methylome arrays and kinase profiles in frozen tumor tissue from groups of patients who do (N=30) and do not (N=30) respond to different agents), to integrate these data from different platforms by means of bioinformatics and to conduct focused functional studies on the results in order to improve understanding of the critical molecular and resistance pathways involved. A large European consortium that has recruited and will recruit large numbers of patients ensures that the new markers identified in a first discovery phase can be tested in a subsequent replication phase. We have the ambition to define new validated risk stratification criteria to be used in personalized patient management. These criteria allow prediction of individual therapy response and resistance and will enable the monitoring of successful treatment outcome while reducing unnecessary drug use and expense.'

Introduzione (Teaser)

Optimisation of a treatment regimen to target an individual condition is a desirable attribute that would maximise the chances of a patient successfully responding to therapy. European scientists set out to define new validated risk stratification criteria that could be used in personalised management of patients with metastatic renal cancer.

Altri progetti dello stesso programma (FP7-HEALTH)

EUROWESTNILE (2011)

European West Nile collaborative research project

Read More  

TRANSCAN (2011)

ERA-NET on Translational Cancer Research

Read More  

HEALTHCOMPETENCE (2009)

Health Competence in Europe

Read More